About 58 results
24 Jun 2013 by B Media Network Health News Editor
Alza Corp. et al. v. Par Pharmaceutical Inc. et al. 1:13-cv-01104; filed June 19, 2013 in the District Court of Delaware Infringement of U.S. Patent No. http://www.jdsupra.com/legalnews/court-report-june-23-2013-85557/.
24 Jun 2013 by Patent Blast
Bausch & Lomb Inc.; Apotex Corp.; Ista Pharmaceuticals, Inc; Nook Media LLC; Barnes & Noble, Inc.; BarnesandNoble.com LLC; Nike Inc; PC Gear Head LLC; K-2 Corporation; Oclaro Inc.; Jensen Group NV; Jensen USA, Inc.; Kalita Co., Ltd.;
Wells Bloomfield, LLC;Amazon.Com, Inc.;. Dickinson Press Inc.; J & D Sales, Inc; HTC America Inc.; Samsung Electrionics America; Samsung Telecommunications America; ..... 24. Alza et. al. v. Par Pharmaceutical et. al.
12 Mar 2012 by Anonymous
Boehringer Ingelheim Pharmaceuticals, Inc et al, Cause No. 3:12-cv-00103, in the U.S. District Court for the Eastern District of Tennessee, Northern Division; and Hawkins et al v. Boehringer Ingelheim Pharmaceuticals Inc et ...
12 May 2013 by Anonymous
Amy Velez, et al., v. Novartis Pharmaceuticals Corp. In the largest gender discrimination case to ever go to trial, Sanford, Wittels & Heisler LLP successfully represented a class of 5,600 female sales representatives of Novartis Pharmaceutical
Company in their gender pay and promotion and pregnancy discrimination claims. A unanimous decision by a jury of nine ... is the switch to single rooms at meetings. If they did work at par it would be a surprising development.
4 Jun 2013 by Anonymous
... and nagging doctors is over. The new pharma model is less is more. ..... Bhasin et al has stipulated to the medical community to not draw conclusions from that study for the general population. His study was done in men 65 ...
7 Jul 2012 by Anonymous
Pharma drugs have multiple patents as they get different indications, IV vs. oral doses, or as the molecule is altered during its lifecycle. Those patent expirations .... That aggressiveness and strong portfolio led to other companies begging us to co
-promote their drugs. Thank GOD for that, ..... The average pain score improvement in trials of the drugs had been in the neighborhood of 30% or more, about what the new Arnold, et al. paper reports. Now, however, at least ...
5 May 2011 by Anonymous
Law360, New York (April 28, 2011) -- IMS Health Inc. has renewed its claims against CVS Caremark Corp. for allegedly breaching contracts to provide the market research firm with prescription data, according to a lawsuit unsealed Wednesday
in ... CVS is represented by Gregory V. Varallo and Scott W. Perkins of Richards Layton & Finger PA and Foley & Lardner LLP is of counsel. ... CVS Pharmacy Inc. et al., case number 6388, in the Delaware Court of Chancery.
9 May 2013 by Anonymous
The case is Velez et al v. Novartis Pharmaceuticals Corp, U.S. District Court, Southern District of New York, No. 04-9194. (Reporting by Grant McCool and Jonathan Stempel in New York; editing by Andre Grenon) © Thomson ...
14 Apr 2011 by Anonymous
Sorin vs. BSC CRM Products Boston Scientific. ... you must be a young pharma rep or you have been eating your company marketing for too long. .... 6) Gillis et al originally published the mean Vp for MVP to be about 17%.
15 Jan 2012 by Anonymous
I feel compelled to disclose what I feel to be even more unethical than cheating, and that is publishing a multi-center trail on a comparing the outcome of diet therapy alone VS UltraMeal 360- a Soy protein drink sweetened with Fructose. My
Metagnics rep. wanted me to read this 2011 paper by Jones et al in J. Clinical Lipidology as he was sure that UltraMeal 360 cures metabolic syndrome. Wile the abstract of this article is convincing, I read the whole paper and was ...